同型胱氨酸尿症中硫化合物的代谢。
Metabolism of sulfur compounds in homocystinurias.
机构信息
Department of Paediatrics and Adolescent Medicine, Charles University - First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
Department of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary.
出版信息
Br J Pharmacol. 2019 Feb;176(4):594-606. doi: 10.1111/bph.14523. Epub 2018 Nov 25.
BACKGROUND AND PURPOSE
Homocystinurias are rare genetic defects characterized by altered fluxes of sulfur compounds including homocysteine and cysteine. We explored whether the severely perturbed sulfur amino acid metabolism in patients with homocystinurias affects the metabolism of hydrogen sulfide.
EXPERIMENTAL APPROACH
We studied 10 treated patients with a block in the conversion of homocysteine to cysteine due to cystathionine β-synthase deficiency (CBSD) and six treated patients with remethylation defects (RMD) and an enhanced flux of sulfur metabolites via transsulfuration. Control groups for CBSD and RMD patients consisted of 22 patients with phenylketonuria on a low-protein diet and of 12 healthy controls respectively. Plasma and urine concentrations of selected sulfur compounds were analysed by HPLC and LC-MS/MS.
KEY RESULTS
Patients with CBSD exhibited plasma concentrations of monobromobimane-detected sulfide similar to appropriate controls. Urinary homolanthionine and thiosulfate in CBSD were increased significantly 1.9 and 3 times suggesting higher hydrogen sulfide synthesis by γ-cystathionase and detoxification respectively. Surprisingly, patients with RMD had significantly lower plasma sulfide levels (53 and 64% of controls) with lower sulfite concentrations, and higher taurine and thiosulfate levels suggesting enhanced cysteine oxidation and hydrogen sulfide catabolism respectively.
CONCLUSION AND IMPLICATIONS
The results from this study suggest that severe inherited defects in sulfur amino acid metabolism may be accompanied by only moderately perturbed hydrogen sulfide metabolism and lends support to the hypothesis that enzymes in the transsulfuration pathway may not be the major contributors to the endogenous hydrogen sulfide pool.
LINKED ARTICLES
This article is part of a themed section on Chemical Biology of Reactive Sulfur Species. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.4/issuetoc.
背景与目的
同型胱氨酸尿症是一种罕见的遗传性缺陷,其特征为包括同型半胱氨酸和半胱氨酸在内的硫化合物通量发生改变。我们探讨了同型胱氨酸尿症患者中严重紊乱的硫氨基酸代谢是否会影响硫化氢的代谢。
实验方法
我们研究了 10 名经治疗的胱硫醚 β-合酶缺乏症(CBSD)患者,由于同型半胱氨酸转化为半胱氨酸的过程受阻,导致患者体内的硫代谢物通量增加,通过转硫途径发生改变;还研究了 6 名经治疗的 remethylation 缺陷(RMD)患者。CBSD 和 RMD 患者的对照组分别由 22 名接受低蛋白饮食的苯丙酮尿症患者和 12 名健康对照组成。采用 HPLC 和 LC-MS/MS 分析了选定的硫化合物的血浆和尿液浓度。
主要结果
CBSD 患者的单溴化亚砜检测到的血浆硫化物浓度与合适的对照相似。CBSD 患者的尿液同型高半胱氨酸和硫代硫酸盐显著增加,分别为 1.9 倍和 3 倍,提示γ-胱硫醚酶的硫化氢合成和解毒作用分别增强。令人惊讶的是,RMD 患者的血浆硫化物水平明显较低(对照组的 53%和 64%),亚硫酸盐浓度较低,牛磺酸和硫代硫酸盐水平较高,提示半胱氨酸氧化和硫化氢分解代谢增强。
结论和意义
这项研究的结果表明,严重的硫氨基酸代谢遗传性缺陷可能仅伴有中度紊乱的硫化氢代谢,并支持这样一种假设,即在转硫途径中的酶可能不是内源性硫化氢池的主要贡献者。
相关文章
本文是关于活性硫物种的化学生物学的专题部分的一部分。要查看该部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.4/issuetoc.html。
相似文献
Br J Pharmacol. 2018-11-25
Br J Pharmacol. 2018-8-23
Br J Pharmacol. 2018-9-27
Br J Pharmacol. 2019-2
J Inherit Metab Dis. 2010-2-17
Br J Pharmacol. 2018-7-1
引用本文的文献
Cell Death Discov. 2025-4-28
Antioxidants (Basel). 2023-4-3
J Oral Biol Craniofac Res. 2023
Free Radic Biol Med. 2022-9
Front Cardiovasc Med. 2021-10-25
Proc Natl Acad Sci U S A. 2021-11-9
本文引用的文献
Br J Pharmacol. 2018-9-27
Biochem Pharmacol. 2017-12-14
Biochem Pharmacol. 2017-12-7
Biochem Pharmacol. 2017-12-1
Br J Pharmacol. 2017-12